Linking Antibodies to
a Better Tomorrow.
We are developing innovative technologies to treat autoantibody-mediated diseases by eliminating pathogenic autoantibodies and the cells that produce them.
Link Therapeutics Inc.
Embedded Files
Our Work
Our Work
Developing Effective Therapies for Autoimmune Diseases
Developing Effective Therapies for Autoimmune Diseases
Dr. Masahiro Shiokawa, Assistant Professor in the Department of Gastroenterology and Hepatology at Kyoto University Graduate School of Medicine, and his group reported that anti-integrin αvβ6 antibodies are produced in patients with ulcerative colitis or primary sclerosing cholangitis and may play a role in disease pathogenesis.
Publications
Ulcerative colitis: Kuwada et al. Gastroenterology. 2021; 160(7)
https://doi.org/10.1053/j.gastro.2021.02.019
Primary sclerosing cholangitis: Yoshida et al. J. Gastroenterol. 2023; 58(8)
https://link.springer.com/article/10.1007/s00535-023-02006-6
Topics
Topics
December 22, 2025 CEO Toru Kawamura Participated in the Kinki Regional Round of “NIKKEI THE PITCH GROWTH”
December 8, 2025 CEO Toru Kawamura Featured on “the University of Karuizawa radio.”
September 18, 2025 Our R&D Featured in the Media
September 18, 2025 Entered into a Joint Research Agreement with KANEKA CORPORATION
September 4, 2025 Selected for AMED’s "Strengthening Program for Pharmaceutical Startup Ecosystem" (9th Call)
July 31, 2025 Our Funding Featured in the Media
July 30, 2025 Series B Funding Round of JPY 850 Million Completed
June 1, 2025 Research Project with Our Participation as Co-Investigator Selected for the AMED FY2025 Translational Research Program (Seeds B)
Company Name： Link Therapeutics Inc.
Established： October 4, 2022
Head Office： Innovation Hub Kyoto 416, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto, Japan
Business Description： Development of therapeutic approaches targeting autoantibodies and
discovery of pathogenic autoantibodies.
Contact
Contact
Report abuse